Home › NDC Lookup › RxCUI directory › RxCUI 2591806

Mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dos... — RxCUI 2591806

RxNorm drug concept · Semantic clinical drug
RxCUI 2591806 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2591806
Official nameMometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asolopatadine HCL 665 MCG/ACTUAT / mometasone furoate 25 MCG/ACTUAT Metered Dose Nasal Spray
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)5,921 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mometasone Nasal Spray: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • You may start to feel some relief within 12 hours of your first dose, but the full benefit usually builds up over several days of consistent, once-a-day use. It works best when you...
  • How soon will I notice this spray actually working?
  • It's approved for preventing seasonal allergy symptoms in children 12 years and older. It is not approved for nasal polyps in anyone under 18. Children under 12 should not use it....
  • Very little of this spray gets absorbed into your bloodstream when used in the nose, so exposure to a baby through pregnancy or breast milk is expected to be minimal. That said, it...
📖 Read our full Mometasone Nasal Spray guide →

🕸️ Concept Web — How Mometasone furoate 0.025 MG/ACTUAT / olopatadine... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray RxCUI 2591806

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Mometasone 108118
    • Olopatadine 135391
    • Mometasone / olopatadine 2591802
    • Mometasone furoate 30145
    • Olopatadine hydrochloride 236599
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ryaltris 2591807
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mometasone / olopatadine Metered Dose Nasal Spray 2591805
    • Mometasone furoate / olopatadine hydrochloride Metered Dose Nasal Spray 2648946
    • Mometasone / olopatadine Inhalant Product 2591803
    • Mometasone / olopatadine Nasal Product 2591804
    • Mometasone furoate / olopatadine hydrochloride Inhalant Product 2659399
    • Mometasone furoate / olopatadine hydrochloride Nasal Product 2659617
    • Mometasone / olopatadine Metered Dose Nasal Spray [Ryaltris] 2591811
    • Mometasone furoate / olopatadine hydrochloride Metered Dose Nasal Spray [Ryaltris] 2655793
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 23 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mometasone furoate 0.025 MG/ACTUAT SCDC · 2591801
  • Olopatadine hydrochloride 0.665 MG/ACTUAT SCDC · 1797893
  • Mometasone / olopatadine Metered Dose Nasal Spray SCDF · 2591805
  • Mometasone furoate / olopatadine hydrochloride Metered Dose Nasal Spray SCDFP · 2648946
  • Mometasone / olopatadine Inhalant Product SCDG · 2591803
  • Mometasone / olopatadine Nasal Product SCDG · 2591804
  • Mometasone furoate / olopatadine hydrochloride Inhalant Product SCDGP · 2659399
  • Mometasone furoate / olopatadine hydrochloride Nasal Product SCDGP · 2659617

Brand-Name Concepts

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2591806 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59467-0700-27 12 CARTON in 1 BOX (59467-700-27) / 1 BOTTLE, SPRAY in 1 CA... Ryaltris HIKMA SPECIALTY USA INC. 2022-08-15
59467-0700-84 12 CARTON in 1 BOX (59467-700-84) / 1 BOTTLE, SPRAY in 1 CA... Ryaltris HIKMA SPECIALTY USA INC. 2022-08-15
68462-0659-27 12 CARTON in 1 BOX (68462-659-27) / 1 BOTTLE, SPRAY in 1 CA... Ryaltris Glenmark Pharmaceuticals Inc., USA 2026-01-13
68462-0659-84 12 CARTON in 1 BOX (68462-659-84) / 1 BOTTLE, SPRAY in 1 CA... Ryaltris Glenmark Pharmaceuticals Inc., USA 2026-01-13
Observed labelers: Glenmark Pharmaceuticals Inc., USA (2) · HIKMA SPECIALTY USA INC. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per gm · median
$7.6684
Range $7.6684–$7.6684 · middle 50% $7.6684–$7.6684 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.